M.T. Gil Agustí

A simple HPLC procedure is described for the determination of bendroflumethiazide (BMFT) in pharmaceutical formulations and urine samples. No interferences from common additives or other drugs frequently administered with BMFT or from endogenous compounds in urine samples were found. The lack of an organic solvent in the mobile phase reduces the risk of environmental contamination and human toxicity.

In this article, the authors present a simple high performance liquid chromatographic procedure for the determination of bendroflumethiazide (BFMT) in pharmaceutical formulations and urine samples. They demonstrate how the lack of an organic solvent in the mobile phase reduces the risk of environmental contamination and human toxicity.